Genentech/Tanox/Ciba to combine anti-IgE antibody development efforts.
Executive Summary
GENENTECH/TANOX/CIBA TO COMBINE ANTI-IGE ANTIBODY DEVELOPMENT for the treatment of allergies and allergic asthma as part of a July 9 settlement of litigation between Genentech and Tanox. Ciba is Tanox' partner for the anti-immunoglobulin E antibody research project under a 1990 agreement. The three companies plan to reach a definitive development agreement in the next six months.
You may also be interested in...
Xolair collaboration settlement
Genentech, Novartis and Tanox settle disagreements over anti-IgE antibody collaboration that includes Xolair. Genentech and Novartis each pay Tanox $3.3 mil. for development costs of TNX-901, an agent with a mechanism of action similar to Xolair; Tanox relinquishes rights to manufacture Xolair in exchange for payments for Xolair produced and accelerated debt forgiveness. The collaboration was the result of a 1996 settlement (1"The Pink Sheet" June 15, 1996, T&G-8)...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011